Oncology Exchange
Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting
Breast Cancer - Emerging Agents in Her2-postitive Breast Cancer
Emerging Strategies for the Management of Recurrent Ovarian Cancer
Non-Hodgkin's Lymphoma - Emerging Agents in Relapse/Refactory Non-Hodgkin's Lymphoma
Gastrointestinal Stromal Tumors - Emerging Multidisciplinary Approaches for the Management of Gastrointestinal Stromal Tumors
Challenges in Treating Renal Cell Carcinoma in the Community
Current Treatment Strategies for Chronic Myelogenous Leukemia
Personalizing Treatment for NSCLC An Oncology Exchange Program
Evidence-based Management of Metastatic Colorectal Cancer
Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients
Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma
Rockpointe.com The confluence of medical science and clinical need

Oncology Exchange:
Emerging Strategies for the Management of Recurrent Ovarian Cancer

A series of Live Grand Rounds Programs, Chapter Meetings, and an on-demand CME-certified Webcourse.

Welcome to Oncology Exchange: Emerging Strategies for the Management of Recurrent Ovarian Cancer. This CME-certified initiative is intended for medical oncologists, gynecologic surgeons, surgical oncologists, oncology nurses, physician assistants, and other health care professionals involved in the care of patients with ovarian cancer. A series of live CME-certified programs will be presented at selected hospitals and ASCO State/Regional meetings throughout the US during 2014/2015, and an online CME-certified webcourse will be available in late 2014.

Program Description:

Despite frequently high rates of response to first-line treatment, 70%-90% of ovarian cancer patients eventually relapse. Several recently approved and investigational targeted agents, including anti-angiogenic agents and PARP inhibitors, have been shown to significantly improve the outlook of patients with recurrent ovarian cancer.

Emerging Strategies for the Management of Recurrent Ovarian Cancer will educate community clinicians on these recent advances in the management of ovarian cancer and help them incorporate evidence-based treatment recommendations into their clinical practices.

Accreditation Statements:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statements:

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information about the accreditation of this program, please email contact@rockpointe-pcme.com.

Calendars for Live Activities

Back to Top

Visiting Professor Series

Chapter Meetings


Related Online Offerings

Back to Top

A calendar of live events, as well as additional CME/CE-certified online activities, for this and other Oncology Exchange programming, can be found at: http://www.medscape.org/sites/advances/oncologyexchange.

Live Program Materials for Speakers and Administrators

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the Visiting Professor Series, "Oncology Exchange: Emerging Strategies for the Management of Recurrent Ovarian Cancer."

This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

  • Review the incorporation of guidelines in clinical decision-making to optimize patient outcomes
  • Evaluate the evidence for personalizing therapy based on genetic mutations and resistance markers
  • Understand the role of PARP inhibitors and antiangiogenic agents for platinum-resistant/sensitive recurrent disease
  • Discuss the integration of ovarian cancer quality measures to improve patient outcomes

Transcript of Speaker Orientation Download (PDF)

Audio download of Speaker Orientation

Audio Download

CME-certified Program Slides

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)

Steering Committee and Speaker Biographies

Back to Top

Deborah K. Armstrong, MDDeborah K. Armstrong, MD
Professor of Oncology
Professor of Gynecology and Obstetrics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD


Deborah K. Armstrong, MD is a Professor of Oncology and Gynecology and Obstetrics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD. After completing her bachelor's in bacteriology at the University of California in Berkeley, CA, she earned her medical doctorate from the George Washington University School of Medicine in Washington, DC. She then completed an internship and residency in internal medicine at the University of Pittsburgh, followed by a fellowship in oncology at the Johns Hopkins University School of Medicine and Hospital.

Dr. Armstong has extensive experience in clinical and translational research in women's malignancies, with a particular focus on ovarian cancer. She serves as the Johns Hopkins' institutional Principal Investigator (PI) for the Gynecologic Oncology Group (GOG, now NRG). She is an active member of the GOG Phase I and Medical Oncology Committees and has been a PI on numerous GOG trials. She is the Co-PI for the Johns Hopkins University NCTN Lead Academic Site Program, and the PI for a number of investigator-initiated and industry-supported clinical trials in gynecologic malignancies. In total, she has more than 20 years of experience with Phase I, Phase II, and Phase III therapeutic clinical trials.

The current Chair of the FDA's Oncology Drugs Advisory Committee, Dr. Armstrong also serves as a Co-chair of the National Comprehensive Cancer Network's Ovarian Cancer Panel, a member of the Department of Defense Peer Review Panels on Breast Cancer and Ovarian Cancer, and as a Co-chair of the Gynecologic Cancer Steering Committee of the Ovarian Cancer Task Force. She has authored or co-authored more than 120 peer-reviewed publications.


Bradley J. Monk, MD, FACOG, FACSBradley J. Monk, MD, FACOG, FACS
Professor and Director, Division of Gynecologic Oncology
Vice Chair, Department of Obstetrics and Gynecology
University of Arizona Cancer Center-Phoenix
Creighton University School of Medicine at Dignity Health
St. Joseph's Hospital and Medical Center
Phoenix, AZ


Bradley J. Monk, MD, FACOG, FACS graduated at the top of his class from the University of Arizona College of Medicine in 1988, and completed a residency in obstetrics and gynecology at the University of California, Los Angeles, in 1992. Between 1988 and 1995, he was the recipient of 3 fellowships in medical genetics and gynecologic oncology. In 1995, Dr. Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center and, from 1998 until recently, was Associate Professor of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, at the Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. Dr. Monk is currently Professor and Director in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph's Hospital and Medical Center in Phoenix, AZ. Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix.

Dr. Monk's research interests include chemotherapy to treat ovarian and cervical carcinoma, biomarkers in gynecologic cancers, and quality of life in women with advanced ovarian cancer. Recently named one of Arizona's "Top Docs" by Phoenix Magazine, Dr. Monk was also awarded the highly prestigious Ernst Wertheim Award. He is on the Board of Directors for the Gynecologic Oncology Group Partners Corporation and is the Cervical and Vulvar Committee Chair for NRG Oncology.

Dr. Monk is a Fellow of the American College of Surgeons, American College of Obstetricians and Gynecologists, and American Society for Colposcopy and Cervical Pathology. He is a current member of the Editorial Boards of several journals, including Gynecologic Oncology and Clinical Ovarian Cancer, and a reviewer for numerous journals, including Clinical Cancer Research, Obstetrics and Gynecology, Cancer, and the Journal of Clinical Oncology. Dr. Monk has authored more than 195 peer-reviewed articles and 28 book chapters dealing predominantly with gynecologic malignancies and patient quality of life.

Back to Top
  and  
This CME-certified activity is jointly provided by Potomac Center for Medical Education and Rockpointe Oncology.
This activity is supported by educational grants from AstraZeneca and Genentech.
©2014 PCME